Date: 2014-09-16
Type of information: R&D agreement
Compound: new antimalarial medicines
Company: Eisai (Japan) the Broad Institute (USA - MA)
Therapeutic area: Infectious diseases - Parasitic diseases
Type agreement:
Action mechanism:
Disease: malaria
Details: * On September 16, 2014, Eisai announced that it has entered into two joint research agreements for the development of new antimalarial medicines. The second agreement is a joint development program with the Broad Institute (Cambridge), a collaborative research facility which involves researchers from Harvard University and the Massachusetts Institute of Technology. Eisai and Broad will work together on the optimization of compounds screened from Broad\'s library. These compounds are believed to be unique as they have a mechanism of action inhibiting protein synthesis, which is completely different to other existing antimalarial medicines. The goal is to identify those with the potential to be effective as new antimalarial medicines. This project was evaluated and was awarded a grant by the Global Health Innovative Technology Fund (GHIT Fund), an international non-profit organization that aims to promote the discovery of new health technologies for eliminating infectious diseases prevalent in developing countries.
Financial terms:
Latest news:
